MedTrace Logo

Losartan Therapy in Pulmonary Hypertension

NCT00519870 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2007-08-23

No results posted yet for this study

Summary

In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

nifedipine, losartan

I: nifedipine 30 mg/d II: losartan 50 mg/d

DRUG

losartan

II: losartan

DRUG

Nifedipine, losartan

I: nifedipine II: losartan

Sponsors & Collaborators

  • Baskent University

    lead OTHER

Principal Investigators

  • Serife Savas Bozbas, MD · Baskent University Faculty of Medicine, Department of Pulmonary Disease

  • Fusun Oner Eyuboglu, MD · Baskent University Faculty of Medicine, Department of Pulmonary Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2005-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519870 on ClinicalTrials.gov